FinRadar.ai

is a deep analytics platform with sophisticated Macro/Micro/Technical/Fundamental actionable data to help you be on the right side of the market

[FinRadar.ai @StuckInStock]

🧵 1/ The deadline for institutional reporting is TODAY.
-Track every fund's holdings
-Find the changes in their positions
-Get your notifications/alerts set up
-Filter the best performers on the quarter, and over time
-Dive deep in the details of every fund
-Create your own baskets of funds...

ALL IN ONE PLACE. DETAILS BELOW
https://t.co/JzkJjrgLtz

[FinRadar.ai @StuckInStock]

Here's a comprehensive breakdown of Macy's $M 's Q1 2026 report — strengths, weaknesses, and stock catalysts:
---

📊 Macy's Q1 2026: In-Depth Analysis
✅ STRENGTHS — Bullish Catalysts
1. Revenue & Comparable Sales — Beating Expectations

Total net sales: $4.7B, up +1.8% YoY (despite ~$40M headwind from closed stores)

Comparable sales: +3.0% — strongest Q1 in 4 years, 5th consecutive beat

Go-forward comp sales: +3.1% — the core, investable business is clearly accelerating
2. Bloomingdale's is a Standout

Comparable sales +10.2% — 7 consecutive quarters of growth, record Q1 sales

This luxury segment commands higher margins and stronger pricing power — a hidden gem inside M
3. Bluemercury Momentum

Comparable sales +6.4% — a high-margin beauty brand in structural growth mode
4. EPS Upside

GAAP diluted EPS: $0.23 vs. $0.13 prior year (+77% YoY) 🔥

Adjusted EPS: $0.13 vs. $0.11 — above guidance

Full-year Adjusted EPS guidance raised to $2.00–$2.20 (from $1.90–$2.10)
5. Guidance Raised Across the Board
| Metric | New FY2026 Guidance | Previous |
|---|---|---|
| Net Sales | $21.5B–$21.75B | $21.4B–$21.65B |
| Comp Sales | +0.5% to +1.2% | -0.5% to +0.5% |
| Adj. EPS | $2.00–$2.20 | $1.90–$2.10 |
6. Strong Balance Sheet & Shareholder Returns
Cash: $1.3B + $2.0B undrawn credit facility
No material debt maturities until 2030 — zero near-term refinancing risk
$50M buyback + $50M dividend in Q1 alone
$1.1B remaining buyback authorization → continued EPS accretion
7. Credit Card Revenue Surging
Credit revenues up +11.7% to $172M — strong consumer credit health, a high-margin stream
8. Technical Setup
Above both 50-day and 200-day SMA ✅
RSI at 63.3 — bullish but not yet overbought

Only -0.11% from 52-week high → price is at a breakout zone

---

⚠️ WEAKNESSES — Risk Factors

1. Gross Margin Pressure

Gross margin: 38.9%, down 30 bps YoY
Entirely attributable to tariff impact (30 bps); excluding tariffs, margins were flat

But tariff risk is not going away — H1 guidance assumes heavier tariff burden
2. Adjusted EBITDA Margin Contracting

Q1 Adj. EBITDA: $290M (5.9%) vs. $304M (6.3%) in Q1 2025

Despite revenue growth, EBITDA dollars and margin both declined — SG&A investments are eating into operating leverage

3. SG&A Creeping Up
SG&A: $2.0B, up $39M YoY — ongoing spending on Reimagine 200, digital, and luxury build-out

As a % of revenue: flat at 39.9%, but absolute cost inflation limits near-term margin expansion
4. Macro & Inventory Risk

Inventories up +3.6% YoY — management says it's "well-positioned," but in a consumer slowdown this could turn into a markdown headwind

Full-year guidance explicitly flags macro/geopolitical uncertainty on discretionary spend

5. TTM Revenue Still in Decline
TTM revenue: $22.6B, down -1.7% YoY — the store closure drag is real and will continue weighing on reported top-line

Net margin TTM: just 2.8% — razor thin for a $5.2B market cap retailer

6. Low Quick Ratio
Quick ratio: 0.28 — very tight liquidity excluding inventory; typical for retail but warrants monitoring

---

🚀 Key Stock Price Catalysts to Watch
| Catalyst | Why It Matters |

|---|---|

| Bloomingdale's & Bluemercury rerating | Luxury/beauty multiples >> department store multiples; spin-off speculation remains a value unlock |
| Buyback acceleration | $1.1B remaining on $2.0B auth; at current $5.2B market cap that's ~21% of float |

| Tariff resolution | Every 30 bps of margin recovery = ~$65M+ in gross profit |

| Comp sales sustaining above 2% | Proves the "Bold New Chapter" is structural, not cyclical |
| Real estate monetization | Hidden asset value in owned properties |

---
🔑 Bottom Line

M is executing better than it has in years. The top-line narrative is inflecting positively, Bloomingdale's is a genuine growth engine, and the balance sheet is clean. The key vulnerability is margin compression from tariffs and SG&A investment — which means the bull case depends on cost discipline and tariff relief in H2 2026.
At $21.67 with a P/E near ~9x forward earnings ($2.10 midpoint), the valuation remains deeply discounted to the S&P — suggesting the market hasn't fully priced in the turnaround yet.

[FinRadar.ai @StuckInStock]

$CELH INSIDER CLUSTER - 3 insiders BUYING
Total: $0.7M (3 transactions)
• Fieldly John (Chief Executive Officer)
• Kravitz Hal
• Hanson Eric (President)

[FinRadar.ai @StuckInStock]

SITUATIONAL AWARENESS LP (Leopold Aschenbrenner)

NEW POSITIONS for Q1 2026:
$TE $AMD $SHAZ $SMH $TSM $HIVE $ASML $MU $GLW $NVDA

via https://t.co/23nEFgCJhU

[FinRadar.ai @StuckInStock]

$SHAK INSIDER CLUSTER - 6 insiders BUYING
Total: $3.2M (9 transactions)
• Balbale Sumaiya
• Chapman Charles J III
• Meyer Daniel Harris
...and 3 more

[FinRadar.ai @StuckInStock]

$BORR - BORR DRILLING LTD Another insider buy coming through -
Currie Jeffrey (Director) bought $1.3M @ $5.31/share
Not a 10b5-1 pre-planned purchase

[FinRadar.ai @StuckInStock]

$CRWD INSIDER CLUSTER - 4 insiders SELLING
Total: $28.1M (16 transactions)
• Podbere Burt W. (Chief Financial Officer)
• Kurtz George (President & CEO)
• Sentonas Michael (President)
...and 1 more

[FinRadar.ai @StuckInStock]

$ADPT INSIDER CLUSTER - 8 insiders SELLING

Total: $14.2M (8 transactions)
Net shares: -1.08M

• BENZENO SHARON
• BOBULSKY SUSAN
• GRIFFIN MICHELLE RENEE
• PISKEL KYLE
• ROBINS CHAD M
...and 1 more

[FinRadar.ai @StuckInStock]

Took a look at the most recent 13F aggregated data for Q1 2026 to find where funds are loading aggressively on any of these:

🟢 $GPN +$3.81B | +30.7% share chg
🟢 $XYZ +$2.16B | +10.4% share chg
🟢 $NKE +$2.14B | +4.9% share chg
🟢 $MRNA +$1.86B | +14.8% share chg
🟢 $ALGN +$1.47B | +15.6% share chg
🟢 $CSGP +$1.49B | +11.6% share chg
🟢 $SWK +$867M | +10.3% share chg
🟢 $CAG +$760M | +15.0% share chg
🟢 $EPAM +$789M | +13.1% share chg
🟢 $CHTR +$804M | +4.4% share chg
🟢 $CPB +$439M | +13.2% share chg
🟢 $POOL +$438M | +6.8% share chg
🟢 $LULU +$423M | +3.9% share chg
🟢 $PSKY +$461M | +20.0% share chg
🟢 $ARE +$304M | +5.4% share chg
🟢 $BAX +$251M | +3.2% share chg
🔴 $PYPL -$681M | -2.6% share chg ← only major outflow

[FinRadar.ai @StuckInStock]

For the funds that have reported so far, $HIMS is seeing a net outflow of $579M in Q1 2026

[FinRadar.ai @StuckInStock]

Good job! careful as many funds report their positions /1000 sometimes, and that can ruin your math or silently generate flaws in the data. Also sometimes a company CUSIP will change, you would see that the fund closed a position (untrue). Also careful with stock splits/reverse splits, they will mess the data...
A very few of the nightmares I had when I coded my platform. Fun to have though!

[FinRadar.ai @StuckInStock]

@MikeLongTerm @BlackRock @PalantirTech Funds did load up on $PLTR in Q1 2026 with + 20+ Billion $ in net fund flows

[FinRadar.ai @StuckInStock]

@SJosephBurns @grok Thought this would be of interest to you Steve. We aggregate all 8.5K+ institutions as they come. Also, this is where $MU for example stands.
https://t.co/wDhUuC5Lbq

[FinRadar.ai @StuckInStock]

https://t.co/kJnwzXoijm

[FinRadar.ai @StuckInStock]

https://t.co/kJnwzXoijm

[FinRadar.ai @StuckInStock]

Some of the healthcare stocks with the heaviest institutional loading based on total share increases, $ flows, $ flow relative to the market cap (from all filers)
$TENX $NKTR $DRUG $ALXO $ SABS $ WAT $AVTX
Full list on the website for every sector or industry

[FinRadar.ai @StuckInStock]

BAKER BROS. ADVISORS — Q1 2026 13F BREAKDOWN
Pure-play biotech fund | $17.1B portfolio
---
 HIGHEST CONVICTION ADDS

$PRAX +63.4% — Praxis Precision Medicine. Biggest add of the quarter. CNS/epilepsy precision therapy 

$KYMR +30.2% — Kymera Therapeutics. Targeted protein degradation. Novel mechanism accumulation

$GRAL +27.9% — GRAIL Inc. Multi-cancer early detection. Liquid biopsy thesis building

$ALKS +23.7% — Alkermes. CNS + addiction medicine. Undervalued pharma getting a Baker look

$KOD +15.1% — Kodiak Sciences. Retinal disease. Quiet but meaningful add

$SMMT +7.9% — Summit Therapeutics. RAS/oncology pipeline momentum

---
 TRIMS (Disciplined Reduction)

$INSM -1.65% — Minor trim on Insmed. Still #4 at $1.15B. Locking in gains, not exiting

$EWTX -10.0% — Edgewise Therapeutics. Cardiac/musculoskeletal. Only notable trim beyond $INSM

---
 MEGA HOLDS (Unchanged, Full Conviction)

$INCY — #1 position, $3.04B, 17.8% of portfolio. Unwavering

$ONC — #2, $2.67B, 15.7%. BeOne Medicines ADR. Rock solid

$MDGL — #3, $1.25B. Madrigal Pharma. NASH/metabolic liver disease

$ACAD — #5, $1.15B. ACADIA Pharma. CNS neuroscience

$CELC — #6, $790M. Celcuity oncology

$RVMD — #7, $753M. Revolution Medicines RAS inhibitor

$RYTM — #10, $600M. Rhythm Pharma. Unchanged — metabolic rare disease

---
 THE THEMES:

 CNS Dominance — $PRAX $ALKS $ACAD = Baker is doubling down on brain

 Novel Mechanisms — $KYMR (protein degradation) + $RVMD (RAS) = cutting-edge science bets

 Early Detection — $GRAL liquid biopsy quietly growing

 Retinal/Rare Disease — $KOD $RYTM $INSM = durable rare disease exposure

 Mature Oncology Core — $INCY $ONC $MDGL anchor the book with proven commercial assets

---
Bottom line: Baker Bros is adding precision CNS + novel mechanism platforms while trimming at the margins. The core $INCY $ONC $MDGL $ACAD block is UNTOUCHED — full conviction on the blue-chip biotech backbone. $PRAX and $KYMR are the clearest new-quarter bets. 

[FinRadar.ai @StuckInStock]

ELLIOTT INVESTMENT MGMT | Q1 2026 | $20.1B Portfolio
19 positions. Hyper-concentrated. Paul Singer 
---
 NEW POSITIONS

$NCLH (Norwegian Cruise Line) — $247M, 1.55% of book. Fresh activist target? 

$RIG (Transocean) — $104M, 0.65%. Offshore drilling conviction play.

---
 INCREASED

$HPE +47% → added 8.8M shares → now $653M (4.1%). Massive enterprise tech bet 

$HDB (HDFC Bank) +268% → nearly tripled. EM banking sleeper pick 

$SDRL +3.5% → small add, consistent energy thesis

---
 DECREASED

$LUV -40.7% → shed 20.8M shares → down to $1.14B (7.2%). Activist campaign winding DOWN 

$MSTR bonds -37.5% → cutting crypto-adjacent debt exposure 

$TFPM -0.4% → tiny trim, still the #1 holding at 29% of book

---
 CLOSED COMPLETELY

$HYG — high-yield ETF hedge? Gone.

$BILL — exited fintech

$ST (Sensata Tech) — out

$FSK (FS KKR) — dumped credit

---
 THE THEMES:

 Energy dominance — $PSX + $SU + $RIG + $SDRL = ~46% of book. Elliott = energy fund now

 Hard assets — $TFPM still 29%. Gold royalty as macro hedge isn't going anywhere

 $LUV exit watch — down 40% this quarter. The Southwest activist play is closing

 Enterprise tech re-rate — $HPE nearly doubled. Undervalued hardware thesis

 Dumping credit — closed $HYG + $FSK. Risk-off on fixed income

---
Bottom line: Elliott is a concentrated Energy + Hard Assets machine with selective activist unwinds.

[FinRadar.ai @StuckInStock]

ICAHN Q4 2025 13F BREAKDOWN — $8.55B portfolio, 12 positions
---

PORTFOLIO CONCENTRATION

77.4% Energy.

Top 3 holdings ($IEP + $CVI + $UAN) = 82.7% of the book

---

MAJOR MOVES

INCREASED (2)

$CVI +1.1% (added 783K shares) — doubling down on his own refiner. Now 28% of portfolio. $2.4B position.

$SD +0.7% (added 36K shares) — small but consistent accumulation in SandRidge Energy

DECREASED (1)

$SATS -58.1% (cut 1.95M shares) — massive trim on EchoStar. Was a merger arb play after the DISH deal fell through. Icahn is walking away.
CLOSED (1)

$SWX GONE — exited Southwest Gas Holdings entirely. The activist campaign there ran its course. He got what he wanted, he's out.
---

THE THEMES

ENERGY CONSOLIDATION — $CVI, $UAN, $SD all held or added. Icahn is leaning harder into energy as a macro theme heading into 2025.
ACTIVIST EXITS — $SWX closed, $SATS slashed.
FORTRESS CORE — $IFF, $AEP, $JBLU, $CTRI, $CZR, $BLCO all unchanged. He's not rotating — he's holding and waiting.
---

BOTTOM LINE
Icahn cleaned house on two activist plays ($SWX, $SATS) and poured the proceeds back into energy. Pure conviction positioning. 77% energy exposure is a bold macro call.

[FinRadar.ai @StuckInStock]

PERSHING SQUARE CAPITAL MANAGEMENT, L.P. - TOP 10 HOLDINGS
New position in $MSFT , Increased position in AMZN
Q: 2026-03-31
via https://t.co/23nEFgCJhU

[FinRadar.ai @StuckInStock]

Perceptive Advisors ($5.1B portfolio) — Q1 2026 13F Breakdown
Pure-play biotech fund. 99.5% Healthcare. Here's what they did
---

CONVICTION ADDS (Massive increases)

$RLAY +412% — Relay Therapeutics, added 7.8M shares. Huge bet on precision oncology pipeline

$SABS +701% — SAB Biotherapeutics, added 5.6M shares. Deep immunology play

$CRVS +231% — Corvus Pharma, tripled position. Cancer immunotherapy

$TENX +230% — Tenax Therapeutics, added 1M shares

$BCRX +135% — BioCryst, added 4.3M shares. Rare disease/plasma protein disorders

$CNTA +80% — Centessa Pharma, added 2.3M shares. Now a 4.1% position

---
18 NEW POSITIONS — Key names:

$IONS · $DAWN · $RVMD · $DMRA · $DBVT · $STRO

Theme: RNA/antisense therapy + emerging oncology platforms

---

CLOSED 38 POSITIONS — Notable exits:

$EXAS · $ACLX · $BSX · $DHR · $FOLD · $PEN

Theme: Dumping large/mega-cap healthcare & diagnostics. Rotating into small-cap biotech

---

TRIMMED HARD:

$APGE -34% — Cut Apogee Therapeutics by 790K shares

$NBIX -80% — Nearly exited Neurocrine

$VRDN -62% — Slashed Viridian Therapeutics

$OMDA -67% — Omada Health gutted

---
📷 The Big Theme:

Perceptive is de-risking large-cap/commercial-stage biopharma and doubling down on early/mid-stage clinical-stage biotech — particularly rare disease, oncology precision medicine, and gene therapy ($MGTX, $SLDB, $DYN all held or added).